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ABSTRACT
Human milk (HM) is the golden standard for nutrition of newborn infants. Human milk oligosaccharides
(HMOs) are abundantly present in HM and exert multiple beneﬁcial functions, such as support of
colonization of the gut microbiota, reduction of pathogenic infections and support of immune
development. HMO-composition is during lactation continuously adapted by the mother to accommodate
the needs of the neonate. Unfortunately, for many valid reasons not all neonates can be fed with HM and
are either totally or partly fed with cow-milk derived infant formulas, which do not contain HMOs. These
cow-milk formulas are supplemented with non-digestible carbohydrates (NDCs) that have functional
effects similar to that of some HMOs, since production of synthetic HMOs is challenging and still very
expensive. However, NDCs cannot substitute all HMO functions. More efﬁcacious NDCs may be developed
and customized for speciﬁc groups of neonates such as pre-matures and allergy prone infants. Here
current knowledge of HMO functions in the neonate in view of possible replacement of HMOs by NDCs in
infant formulas is reviewed. Furthermore, methods to expedite identiﬁcation of suitable NDCs and







Breast milk is the golden standard for nutrition of newborn
infants (Walker 2010). It is evolutionary optimized and provides
newborns with all essential nutrients needed in the ﬁrst months
of infancy (Breastfeeding and the Use of Human Milk 2012;
Oftedal 2012). The composition of human milk (HM) is highly
variable in time and changes in response to many factors to meet
the infant’s requirements according to its age (Ballard and
Morrow 2013). HM is therefore considered to be a dynamic com-
plex bio ﬂuid and contains a wide range of varying amounts of
proteins, lipids and carbohydrates. It is widely believed that the
composition of HM is speciﬁcally tailored by individual mothers
to meet the requirements of the neonate (Walker 2010). Especially
human milk oligosaccharides (HMOs) have gained considerable
attention in that respect. HMOs are known to exert prebiotic
effects and thereby play an essential role in guidance and the
development of a healthy microbiome (Smilowitz et al. 2014).
1.2. The effect of human milk oligosaccharides on
microbiota development
Although highly regulated, colonization of the neonatal gut by
the microbiota is a very vulnerable period (Rautava et al. 2012).
Usually the infant gut is ﬁrst colonized by bacteria derived
from the mother. The ﬁrst microorganisms invading the infant
include aerobic or facultative anaerobic bacteria, which create a
new environment that promotes the colonization of strict anae-
robes such as Biﬁdobacteria, Clostridia and Bacteriodes (Adler-
berth and Wold 2009; Morelli 2008). This colonization is
inﬂuenced by many factors such as the mode of delivery,
hygienic circumstances and feeding practice (Figure 1) (Toole
and Claesson 2010). Breastfeeding is involved in maturation of
microbiota by providing stimulating components that serve as
feed for speciﬁc bacterial species to ensure an enrichment of
key members of the gut microbiota. Speciﬁc HMOs have been
shown to stimulate the growth of Biﬁdobacteria (Karav et al.
2016). As reduced numbers of Biﬁdobacteria species are associ-
ated with the development of atopic diseases in later life,
HMOs are relevant components of HM (Penders et al., 2006).
1.3. Effects of HMOs on gut health and immune system
development
As indicated above, healthy colonization of the gut is of great
importance for general health of the infant, but it is especially
important for the development of an effective gut barrier
function and the establishment normal immune responses
(Kleessen et al. 2001; Rautava et al. 2012) and HMOs play a big
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role in this. The gut barrier consists of the resident microbiota,
a mucus layer, epithelium and resident or recruited immune
cells, to provide defense against pathogens and their toxins
secreted in the lumen. However, immune responses in new-
borns are immature. This immaturity is characterized by a
decreased ability of fetal monocytes and granulocytes to
respond to lipopolysaccharide, while the immature fetal adap-
tive immune response is characterized by a dominant
Th2type response and a lack of a Th1 type immune response
and a relative lack of immunological memory (Simon et al.
2015). HMOs play a role in the maturation of the infant
immune system: in addition to the effects on the maturation
through microbiota, as described above, HMOs also exert direct
immune modulating effects (Kulinich and Liu 2016).
1.4. NDCs to replace HMOs in infant formula: Effects on
microbiota and the immune system
HMOs are unique for HM and not found in the same composi-
tion and diversity in animal milk (Kunz et al. 2000). This
imposes an issue for infants for whom consumption of mother
milk is not an option, and cow milk derived infant formulas
have to be fed. During recent years, much effort has been
directed to ﬁnd carbohydrates that might substitute some of
the HMO functions. HMO supplementation of cow milk infant
formulas is still too expensive for broad application. Nowadays
cow-milk derived infant formulas are therefore often supple-
mented with affordable non-digestible carbohydrates (NDCs)
such as galacto-oligosaccharides (GOS) and fructo-oligosac-
charides (FOS) to substitute for some of the HMO functions
(Vandenplas et al. 2015). Although beneﬁcial effects of these
carbohydrate supplementations have been reported on
prevention of allergy and atopic dermatitis (Hoffen et al. 2009;
Rijnierse et al. 2011), it remains largely unclear by which mech-
anisms these effects are accomplished. Furthermore, there are
more potentially beneﬁcial NDCs available which might be
suitable for the supplementation of infant formulas.
This review is focusing on current knowledge of HMO-func-
tions and its structures. Different beneﬁcial effects of HMOs are
discussed. Identiﬁcation and understanding HMO-functions is
important for proposing NDCs that might serve as substitute.
The functional effects of these HMOs should be partly or
completely substituted by NDC in infant formula. Currently
applied NDCs are discussed, but as better NDCs might become
available for babies with health issues, also test systems repre-
sentative for effects in babies are presented and discussed.
2. Human milk oligosaccharides
2.1. HMO structures and compositions
HMOs constitute a heterogeneous mixture of glycans that vary
per individual (Chaturvedi et al. 2001). The amount of HMOs
in HM are dependent on the stage of lactation and varies from
around 20.9 g/L in colostrum to 12.9 g/L in mature milk
(Coppa et al. 1993). HMOs contain 3 to 22 saccharide units per
molecule and are made up of 5 building blocks (Figure 2a):
glucose (Glc3), galactose (Gal), N-acetylglucosamine (GlcNAc),
fucose (Fuc) and sialic acid (Neu5Ac) monosaccharides (Bode
2015). Although the combinatorial potential is immense, only
about 200 different compositions of HMOs have been charac-
terized (Wu et al. 2012). These are classiﬁed in 13 groups
according to their core structures. All HMOs consist of a lac-
tose core (Galb1–4Glc) (Figure 2b), which forms the reducing
end (Kunz et al. 2000). The core HMO structures can be further
elongated enzymatically by b1–3 or b1–6 linkage to either
Galb1–3GlcNAc (type-1 chain) or to Galb1–4GlcNAc (type-2
chain) (Figure 2c) (Bode 2015). The core structures can be dec-
orated with fucose (Fuc) and sialic acids residues. Fuc can be
attached by a1–2, a1–3, or a1–4 linkages and/or sialic acids are
connected with a2–3 or a2–6 linkages at the terminal positions
(Figure 2d) (Bode 2015).
All HMOs are synthesized in the mammary gland. The qual-
itative and quantitative composition of HMOs depends on the
expression of speciﬁc transferases enzymes in lactocytes (Bode
2015). Secretor (Se) and Lewis (Le) blood group genes are two
important gene groups for HMO proﬁles (Johnson and Wat-
kins 1992; Kumazaki and Yoshida 1984; Stahl et al. 2001). The
Se gene encodes for the a1–2-fucosyltransferase enzyme
(FUT2) and is expressed in so-called ‘secretors’ (Kumazaki and
Figure 1. Factors inﬂuencing the composition and colonization of newborns gut
microbiota.
Figure 2. HMO structures. (A) HMO building blocks, (B) Possible linkages of HMO building blocks, (C) type 1 and type 2 chains and (D) structures of 20FL, 30FL and 60SL
HMOs.
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Yoshida 1984). FUT2 is responsible for a1–2 linkage of Fuc to
the terminal Gal of the type 1 chain of HMOs. Therefore, secre-
tor mothers can produce a1–2-fucosylated components such as
20-fucosyllactose (Fuca1–2Galß1–4Glc) and lacto-N-fucopen-
taose (Fuca1–2Galß1–3GlcNAcß1–3Galß1–4Glc). Activation
of the Le-gene results in expression of a1–3/4-fucosyltransfer-
ase (FUT3), which is responsible for a1–4 linkage of Fuc to a
subterminal GlcNAc of the type 1 chain of HMOs (Johnson
and Watkins 1992). Fuc attachment to a subterminal GlcNAc
of the type 1 chain by an a1–4 linkage through FUT3 results in
the presence of Le a-sugars in nonsecretor milk (Le aCb¡) and
Le b-sugars in secretor’s milk (Le a-bC) (Stahl et al. 2001). In
Le-negative women (Le a-b-) this leads to an absence of these
sugars, in both secretors and nonsecretors. As a result there are
four different groups of mothers: SeCLeC, Se-LeC, SeCLe-
and Se-Le-. There might be other factors inﬂuencing HMO bio-
synthesis as well, as a recent study by McGuire et al. (McGuire
et al. 2017) showed that HMO concentrations and proﬁles vary
geographically, even when secretor (Se) and Lewis (Le) blood
group genes were taken into account.
2.2. Currently known HMO functions
Many different HMOs functions have been identiﬁed, includ-
ing functions such as selectively enriching gut bacteria and
thereby inﬂuencing microbiota composition (Garrido et al.
2011), preventing pathogen adhesion to epithelial cells
(Jantscher-Krenn et al. 2012; Ruiz-Palacois et al. 2003), enhanc-
ing intestinal epithelial barrier function (Holscher et al. 2014)
and preventing infection and supporting immunity (Naarding
et al. 2005). These effects are all potentially beneﬁcial for the
neonate (Figure 3). In the next sections the functions are brieﬂy
reviewed.
2.2.1. Effects of HMOs on microbiota composition
Because of a lack of glycoside hydrolases and intestinal mem-
brane transporters, HMOs are not digested in the upper part of
the gastrointestinal tract of infants (Engfer et al. 2000; German
et al. 2008). As a consequence the majority of HMOs reach the
colon, where they serve as a substrate for speciﬁc microbes,
inﬂuencing both the composition and activity of the gastroin-
testinal microbiota (Garrido et al. 2011). HMOs are speciﬁcally
known to inﬂuence populations of beneﬁcial microorganisms,
such as Biﬁdobacterium (Garrido et al. 2011), a dominant spe-
cies in the intestine of breast-fed infants. These bacteria have
the ability to utilize HMOs, depending on their equipment with
dedicated glycoside hydrolases, transporters and other mole-
cules contributing to degradation (Goh and Klaenhammer
2015). As certain bacteria such as Biﬁdobacteria and Lactoba-
cilli speciﬁcally express sialidases to cleave Sia and fucosidases
to cleave Fuc, it is believed that these species co-evolved with
HMOs (Garrido et al. 2016; LoCascio et al. 2007; Sela et al.
2012; Ward et al. 2006).
Although there are multiple Biﬁdobacteria species that can
utilize HMOs, there are also Biﬁdobacterica species that utilize
HMOs to a lesser extent (Sela et al. 2012). This ability to utilize
HMOs depends on the enzymes the Biﬁdobacteria are equipped
with. Biﬁdobacterium longum supsp. Infantis (B. infantis), a key
infant gut microbe, possesses a large cassette of genes associated
with HMO consumption, enabling this subspecies to grow to a
high density on a broad array of HMOs as sole carbon source
(Marcobal et al. 2010). Other subspecies may only be able to
consume structures of limited diversity (Sela et al. 2012). It
is believed that subspecies B. infantis ATCC 15697 imports
intact HMOs and subsequently deconstructs them with intra-
cellular glycoside hydrolases, such as a-fucosidases, a-siali-
dases, b-galactosidases and N-acetyl- b-D-hexosaminidases
(Sela et al. 2012). Other species of Biﬁdobacterium, such as B.
biﬁdum, degrate HMOs using extracellular glycosidases and
transport mono-, di-, or oligosaccharides rather than whole
HMO complexes (Garrido et al. 2011; Marcobal et al. 2010;
Yoshida et al. 2012). Biﬁdobacteria can selectively grow and
thrive in the infant gut, since they have the advantage of being
able to utilize HMOs over other bacteria that cannot utilize
HMOs. The species that cannot utilize HMOs have a disadvan-
tage and do not readily colonize. However, HMOs do not only
serve as substrate for bacteria but they can also enhance Biﬁdo-
bacteria persistence in the gastrointestinal tract by increasing
their ability to bind to epithelial cells (Chichlowski et al. 2012;
Kavanaugh et al. 2013). In the study of Wickramasinghe and
collegues (Wickramasinghe et al. 2015) it was found that both
strain and carbon source affect binding afﬁnity of Biﬁdobacte-
ria to epithelial cells. Furthermore they found that HMO-fed
Biﬁdobacteria have more anti-inﬂammatory effects in human
gut intestinal Caco-2 cells, when compared to Biﬁdobacteria
grown on other carbon sources, such as glucose and lactose.
HMO metabolites, or so-called ‘post-biotics’, derived from
fermentation of HMOs by Biﬁdobacteria can have beneﬁcial
effects as well, as they stimulate growth of other members of the
gut microbiota. In a study by Asakuma et al. (Asakuma et al.
2011) different Biﬁdobacteria species were grown on media con-
taining a main neutral oligosaccharide fraction. They found that
B. biﬁdum used secretory glycosidases to degrade HMOs, but
degraded HMOs were left outside the cell, indicating that differ-
ent species can share produced sugars. Fermentation of those
sugars by other species can result in the production of the short
chain fatty acids (SCFAs) such as butyrate and propionate. Both
butyric acid and propionate are important for gut health as they
can interact with host epithelium to stimulate mucin release,
Figure 3. Beneﬁcial effects of human milk oligosaccharides (HMOs). HMOs can
speciﬁcally stimulate growth of (A) Biﬁdobacteria and (B) Lactobacilli, competing
with and resulting in (C) a lower number of pathogens. Furthermore, HMOs can
(D) compete with viruses for uptake by C-lectin receptors on dendritic cells and (E)
act as pathogen binding decoy receptors to prevent binding of pathogens to gly-
can structures on epithelial cells. HMOs can also (F) inﬂuence epithelial cell prolifer-
ation, (G) enter the systemic circulation, (H) alter the glycogalyx and fermentation
products of HMOs and (I) post-biotics for other microbiota species.
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increase mucosal blood ﬂow and modulate the immune system
(Pl€oger et al. 2012; Reichardt et al. 2014). Schwab and colleagues
(Schwab et al. 2017) found a trophic interaction between Biﬁdo-
bacteria and Eubacterium hallii (E. hallii), a common member
of the adult gut microbiota, during L-fucose degradation. In a
single culture E. hallii was not able to grow on L-fucose. In co-
cultures B. Longum subsp. Infantis was able to utilize L-fucose
and produced 1,2-propanediol (1,2-PD), which was used by E.
hallii to produce propionate.
2.2.2. HMOs and prevention of pathogen adhesion
HMOs can prevent adherence of bacterial and protozoan-para-
sitic pathogens to gut epithelial cells by acting as soluble decoy
receptors (Jantscher-Krenn et al. 2012; Ruiz-Palacios et al.
2003). They block a crucial step in the binding of pathogens to
cell surface sugars (glycans), also known as the glycocalyx, pres-
ent on gut epithelial cells (Springer and Gagneux 2013). These
glycans are conjugated to lipids or proteins (Huang et al. 2016).
HMOs resemble some of the glycan structures of glycocalyx
sugars, allowing competition with pathogen receptors. Patho-
gens that recognize and bind to HMOs will pass the intestinal
tract without binding to epithelial cells preventing infection of
the neonate (Bode 2015). An example is the pathogenic micro-
organism Campylobacter jejuni (C. jejuni). Infections with C.
jejuni can have signiﬁcant impact on infant health as it can
cause diarrhea, the most common cause of infant mortality
(Liu et al. 2012). 20-fucosyllactose (20FL) HMOs serve as a solu-
ble decoy receptors for C. jejuni, reducing binding and coloni-
zation of the pathogen (Ruiz-Palacios et al. 2003). This results
in a lower incidence of diarrheal episodes in breast-fed chil-
dren. Jantscher-Krenn et al. (Jantscher-Krenn et al. 2012)
found that Lacto-N-tetraose HMOs also prevent the attach-
ment of the protozoan parasite Entamoeba histolytica, conﬁrm-
ing the anti-adhesives properties of HMOs.
2.2.3. Effects of HMOs on epithelial cell responses
HMOs do not only impact microbes or can serve as decoy
receptor for pathogens, but can also directly inﬂuence host cell
responses against pathogens and modify e.g. the glycogalyx
(Angeloni et al. 2005). A study of Kuntz et al. (Kuntz et al.
2008) showed that both neutral and acidic HMO fractions
modulate intestinal epithelial cell apoptosis, proliferation and
differentiation and Angeloni et al. (Angeloni et al. 2005) found
that HMOs can alter epithelial cell gene expression, leading to a
different expression of cell surface glycocalyx. A different
expression of glycocalyx molecules changes the ability of cer-
tain pathogens to bind to the cell surfaces (Bode 2006). The
HMO 30SL speciﬁcally reduces the expression of sialyltransfer-
ase ST3Ga11, ST3Ga12 and ST3Ga14, leading to less binding
of sialic acid groups to glycans (Angeloni et al. 2005). As a
result, species that speciﬁcally bind to glycans containing sialic
acid groups, such as E. Coli, will have lower ability to bind to
epithelial cells (Bode 2006). Recently, Holscher et al. (Holscher
et al. 2014) found that HMOs play a role in maturation of epi-
thelial cells as well. In this study, HT-29 and Caco-2Bbe cell
lines were used to build a model of the crypt-villus axis and the
effects of lacto-N-neotetraose (LNnT), 20FL, and 60- sialyllac-
tose (60SL) on differentiation of epithelial cells were tested. All
three HMOs tested reduced cell proliferation, suggesting a
speciﬁc role for HMOs in the maturation of the gastrointestinal
tract (Holscher et al. 2014).
2.2.4. Effects of HMOs on prevention of infection and
support of immunity
HMOs can also prevent infection of viruses by competing for
binding to receptors. Glycans are recognized by the carbohy-
drate receptors C-type lectins on DCs, speciﬁc tissue macro-
phages and other myeloid antigen presenting cells (Cummings
and McEver 2009). C-type lectins belong to the family of anti-
gen uptake receptors as they recognize glycans on the cell sur-
face of many viruses, bacteria and parasites (Cummings and
McEver 2009). Many viruses are known to use this receptor to
infect the host (Huang et al. 2016). Upon binding viruses can
hide in DCs for several days in order to escape from the
immune system (Hong et al. 2009). HMOs can prevent infec-
tion via this pathway. A well-characterized pathogen pattern
recognition-receptor (PPR) C-type lectin involved in infection
is dendritic cell-speciﬁc intercellular adhesion molecule-3-grab-
bing non-integrin (DC-SIGN). This receptor recognizes man-
nose-containing glycol-conjugates, but has an even higher
afﬁnity for fycosylated structures such as Lewis antigens. HM
contains monomeric Lewis epitopes that bind to DC-SIGN and
thereby compete with pathogen binding, resulting in lower
infection rates of for example HIV-1 (Naarding et al. 2005).
DC-SIGN binding by HMOs might also be an important
mechanism by which HMOs contribute to immune maturation
in infants as this receptor induces adaptive immune responses
(Engering et al. 2002). The DC-SIGN receptor internalizes anti-
gen after activation and presents it to other immune cells,
thereby initiating various immune responses. The outcome of
the response depends on the interplay between DC-SIGN and
Toll like receptor (TLR) signalling and the type of glycan it
interacts with (Van Vliet et al. 2008). DC-SIGN is considered
to play an important role in the induction of immune tolerance
and maintenance of homeostasis by modiﬁcation of T cell
responses (Garcia-Vallenjo and van Kooyk 2009).
HMO effects are not only seen locally in the gut, but can also
be systemic as HMOs can pass the gut-barrier (Rudloff et al.
2012). Presence of HMOs in urine of infants indicates that
HMOs are absorbed into the bloodstream (Rudloff et al. 2012).
Blood absorbed HMOs have been shown to reduce invasion of
uropathogenic Escherichia coli (E. coli) by interacting with ure-
ter epithelial cells, making them more resistant against E. coli
invasion by a suppression of intracellular signaling of apoptotic
pathways (Lin et al. 2014). As a result epithelial cells cannot
respond to E.coli bacteria. These effects were only observed
with the HMO 30-sialyllactose (30SL) (Lin et al. 2014). 20FL
HMOs can directly inﬂuence inﬂammatory reactions as well
(He et al. 2014). Recently, He et al. (He et al. 2014) found that
HMOs and 20FL HMOs can also directly inhibit LPS-mediated
inﬂammation during invasion of enterotoxigenic E. coli in T84
and H4 intestinal epithelial cells.
3. Use of non-digestible carbohydrates in infant
formula
For a variety of reasons not all infants can be fed with HM.
Infants that do not receive HM are routinely fed with cow-milk
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derived infant formulas, which do not contain HMOs. Since the
production of synthetic HMO-like structures is challenging and
still very expensive due to the complexity of HMOs, many cow-
milk derived infant formulas are nowadays supplemented with
non-human oligosaccharides. In the next section, we will dis-
cuss similarities in functional effects between HMOs and
NDCs. As galacto-oligosaccharides (GOS), fructo-oligosacchar-
ides (FOS) and pectin-oligosaccharides (POS) are the most
commonly applied, the focus will be on these molecules.
3.1. Galacto-oligosaccharides
Galacto oligosaccharides (GOS) are comprised of galactose
units with one glucose unit at the reducing end. The length of
the chain typically ranges from 2 to 10 units with variations in
branching and glycosyl linkage (Ackerman et al. 2017). Glyco-
syl linkages include b1,3, b1,4 and/or b1,6. The type of linkage
is determined by the enzyme source used to link the different
units (Ackerman et al. 2017; Intanon et al. 2014). Like HMOs,
GOS can reach the large intestine, where they can act as prebi-
otics (Macfarlane et al. 2008). For this reason, multiple studies
focused on the effect of GOS in infant formula on microbiota
composition, as well as on the direct effects GOS can have on
epithelium or immune cells in the large intestine.
3.1.1. Effects of GOS on microbiota composition
GOS has many beneﬁcial effects on microbiota. In a study
of Ben et al. (Ben et al. 2004) infant formula substituted
with 2.4 g/l GOS was fed to term infants. Human milk and
infant formula without GOS were used as a positive and
negative controls respectively. After 3 and 6 months, intesti-
nal Biﬁdobacteria and Lactobacilli numbers were signiﬁ-
cantly increased in infants fed with GOS supplemented
infant formula compared to infants fed with infant formula
without GOS. There were no signiﬁcant differences between
mother milk and GOS supplemented infant-formula.
Another study by Fanaro et al. (Fanaro et al. 2009) also
showed that addition of 5 g/L GOS to infant formula
increased numbers of Biﬁdobacteria. In this study 4–6
month old infants were fed with formula with or without
GOS and numbers of Biﬁdobacteria were studied at 6 and
12 weeks after the start of the study (Fanaro et al. 2009).
Watson et al. (Watson et al. 2013) also showed in vitro that
GOS and lactulose supported favorable growth of Biﬁdobac-
teria and Lactobacilli strains when cultured as single strains
under anaerobic conditions. More beneﬁcial effects of GOS
on microbiota composition have been extensively reviewed
by Macfarlane et al. (Macfarlane et al. 2008).
3.1.2. GOS and prevention of pathogen adhesion
Like HMOs, GOS can also act as soluble decoy receptors to pre-
vent the adhesion of pathogens to gastrointestinal epithelial
cells. A study by Shoaf et al. (2006) investigated the effect of
GOS on the adherence of enteropathogenic Escherichia coli
(EPEC) in an in vitro study using HEp-2 and Caco-2 cell lines
(Shoaf et al. 2006). Puriﬁed GOS could reduce adherence of
EPEC to HEp-2 and Caco-2 cell by 65 and 70% respectively.
Adherence inhibition of pathogens was dose dependent and
reached a maximum at 16 mg/ml (Shoaf et al. 2006).
3.1.3. Effects of GOS on epithelial cells responses
GOS also has effects on intestinal epithelial cells and has been
reported to stimulate gut barrier function (Bhatia et al. 2015).
An in vitro study by Bhatia et al. (Bhatia et al. 2015) showed
that GOS enhanced intestinal barrier function through modula-
tion of the secretory function of human goblet cells by up regu-
lation of related genes and protein expression (Bhatia et al.
2015). GOS can also stimulate in vitro tight junction assembly
in gut intestinal human Caco-2 cells, which is beneﬁcial for the
integrity of the epithelial barrier (Akbari et al. 2015). Further-
more, GOS can prevent deoxynivalenol-induced histomorpho-
logic alterations in the villi of the mouse intestine, indicating
that it has protective effects on villi as well, which is important
for undisturbed adsorption of nutrients (Akbari et al. 2015). In
another study by Akbari et al. (2017) it was found that GOS
could beneﬁcially inﬂuence barrier integrity of Caco-2 cells in
vitro. Incubation with GOS had a protective effect on deoxyni-
valenol-induced impairment of the monolayer integrity by
inducing acceleration of the tight junction reassembly. Also,
GOS had reducing effects on release of the inﬂammatory
marker CXCL8 by the cells (Akbari et al. 2017).
3.1.4. Effects of GOS on prevention of infection and support
of immunity
Alizadeh and coworkers (2016) studied the effect of GOS
supplementation on the intestinal immune system using a
neonatal piglet model. Piglets were used as the maturation of
the intestines in piglets are considered to closely resemble that
of human neonates and infants (Alizadeh et al. 2016). In this
study, piglets were fed with milk formulas with or without GOS
for 3 or 26 days. It was found that GOS substitution supported
intestinal development. Also, mRNA expression levels of por-
cine b-defensin-2, and sIgA levels in saliva were increased in
animals fed with GOS, suggesting an improvement of mucosal
immune responses (Alizadeh et al. 2016).
3.2. Fructo-oligosaccharides
Fructans comprise a heterogeneous group of polymers com-
posed of a linear chain of fructose units terminated by a glucose
residue with variation in glycosidic linkage and degree of poly-
merization. Chain lengths can vary from 2 to up to 200 resi-
dues. In this section we will discuss effects of short chain FOS
(scFOS), which have between 3 and 5 residues per chain and
oligofructose (or long chain FOS (lcFOS)) that have 6 to 10 res-
idues. scFOS are naturally present and can be extracted from
sources like chicory. Both scFOS and lcFOS can also be pro-
duced enzymatically from inulins obtained from natural sour-
ces such as chicory and sugar beet (Singh et al. 2016)
3.2.1. Effect of FOS on microbiota composition
Like GOS and many HMOs, scFOS reaches the colon where
it might selectively stimulate the growth of Biﬁdobacteria
(Macfarlane et al. 2008). In vitro studies have shown that
strains of Biﬁdobacterium animalis and Biﬁdobacterium lon-
gum are able to utilize scFOS (Valdes-Varela et al. 2017) as a
carbon source. Bouhnik et al. (Bouhnik et al. 1996) studied the
effect of a mixture of FOSs on fecal Biﬁdobacteria numbers.
Healthy adults received 12.5 g/day FOS for a period of 12 days.
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FOS ingestion led to a signiﬁcant increase in Biﬁdobacteria
numbers compared to placebo groups. Another study by Bouh-
nik and colleagues (Bouhnik et al. 2004) also demonstrated the
biﬁdogenic effects of scFOS. However, the biﬁdogenic effect of
scFOS seems to be dose dependent (Bouhnik et al. 1999). A
study performed by Paineau and coworkers (Paineau et al.
2014) demonstrated that scFOS also has a biﬁdogenic effect in
infants fed with formula supplemented with scFOS. In those
infants, fecal concentrations of Biﬁdobacteria increased at the
age of 2 and 3 months compared to placebo groups (Paineau
et al. 2014). Fermentation of lcFOS seems to be more selectively
than scFOS. Marx and colleagues (Marx et al. 2000) found that
many different Biﬁdobacterium strains are capable of utilizing
scFOS during in vitro fermentation, but B. adolescentis was the
only strain that successfully metabolized lcFOS and fructans of
other chain lengths. This implies that lcFOS can selectively
stimulate growth of B. adolescentis. scFOSs do not only inﬂu-
ence Biﬁdobacteria numbers. A study by Respondek et al.
(Respondek et al. 2013) evaluated the effect of scFOS on micro-
biota composition and metabolic parameters in a mice model
harboring the human-type microbiota and with diet-induced
obesity. Addition of scFOS to a high-fat diet did not only
increase fecal Biﬁdobacteria, but also Clostridium coccoides,
whereas Clostridium leptum numbers decreased. The changes
in numbers of Clostridium bacteria could be correlated to meta-
bolic changes. This indicates scFOS can induce profound meta-
bolic changes by modulation of the intestinal microbiota
(Respondek et al. 2013).
3.2.2. Effects of FOS on prevention of infection and support
of immunity
ScFOS has anti-pathogenic and immune stimulating functions.
Paineau et al. (2014) studied the effect of scFOS substitution on
fecal antipoliovirus IgA levels in infants at 4 months of age.
Although the enhancing effect was not signiﬁcant, speciﬁc IgA
levels tended to be higher in the group of infants fed with for-
mula with scFOS compared to the placebo group. This might
indicate that scFOS can stimulate mucosal immune develop-
ment (Paineau et al. 2014). Other studies involving animal
experiments support this. Swanson and colleagues (Swanson
et al. 2002) studied FOS effects on gut health in healthy adult
dogs by examining microbial populations and fermentation
products. In this study, FOS appeared to enhance parameters
of gut health by positively altering gut microbial ecology and
fecal protein catabolites (Swanson et al. 2002). Hosono and
coworkers (Hosono et al. 2003) investigated the immunological
inﬂuences of FOS in mice. In this study, mice received 0–7.5%
FOS for 6 weeks. Mice that received 2.5% FOS had a signiﬁcant
higher fecal IgA levels. IgA secretion by Peyer’s patch cells was
upregulated in a dose dependent manner in response to FOS.
CD4C T-cells from the Peyer’s patches showed a dose-depen-
dent increase in production of interferon-Y and interleukin IL-
10. In addition, a high response in IL-5 and IL-6 production
was found. Together, these data suggest that FOS can change
the intestinal immune environment (Hosono et al. 2003). Fur-
thermore, Le Bourgot et al. (Le Bourgot et al. 2016) found that
a scFOS supplementation could stimulate inﬂuenza vaccine
responses in weaning pigs. The pig diets were supplemented
with 0.15% scFOS for 7 weeks. Post weaning, the scFOS diet
increased anti-inﬂuenza IgA levels in pig serum and feces.
A mechanism by which FOS can possibly inﬂuence mucosal
immunity is by reducing intestinal inﬂammation. Zenhom
et al. (2011) investigated the effect of FOS on the expression of
the peptidoglycan recognition protein 3 (PGlyRP3) in an in
vitro experiment using Caco-2 cells. Activation of this receptor
reduces the expression of proinﬂammatory cytokines. FOS
could induce PGlyRP3 in a dose and time dependent manner.
However, when PPARg was antagonized, PglyRP3 production
was inhibited. When Caco-2 cells were transfected with speciﬁc
small interfering RNA targeting PGlyRP3, the anti-inﬂamma-
tory effects of FOS, measured by cytokine release and expres-
sion and NF-kB translocation, were abolished. This might
indicate that FOS exerts an anti-inﬂammatory effect by induc-
ing nuclear PPARg, which regulates the anti-inﬂammatory
PGlyPR3 (Zenhom et al. 2011). FOS also has direct effects on
gut barrier function. Akbari et al. (2017) investigated the effect
of FOS on epithelial integrity using an in vitro Caco-2 mono-
layer cultured on transwells. Incubation with 2% FOS could sig-
niﬁcantly modulate deoxynivalenol-induced epithelial barrier
disruption measured by transepithelial electrical resistance and
paracellular ﬂux of luciferase yellow (Akbari et al. 2017).
3.3. Mixtures of galacto-oligosaccharides and fructo-
oligosaccharides
Mixtures of GOS and FOS are already widely added to infant
formulas distributed in Europe. Currently, GOS and FOS are
added in a ratio of 9:1. This ratio was chosen to mimic the
molecular size distribution of HMOs (Knol et al. 2005).
3.3.1. Effects of GOS/FOS mixtures on microbiota
composition
Knol et al. (Knol et al. 2005) found that infant formula supple-
mented with a mixture of GOS and FOS (in a ratio of 9:1, oligo-
saccharide formula, OSF-group) had stimulating effects on the
growth of Biﬁdobacteria and the metabolic activity of the total
intestinal ﬂora (Knol et al. 2005). Fermentation proﬁles of
infants fed with infant formula supplemented with GOS/FOS
were closer to that observed in breast-fed infants compared to
infants fed with control formula lacking the NDCs.
3.3.2. GOS/FOS mixtures and prevention of pathogen
adhesion
There are no speciﬁc studies investigating the effect of a GOS/
FOS mixture on the prevention of pathogen adhesion to epithe-
lial cells. However, because GOS can prevent pathogen adhe-
sion (Shoaf et al. 2006), it is likely that GOS in a mixture with
FOS can also prevent pathogen adhesion.
3.3.3. Effects of GOS/FOS mixtures on epithelial cell
responses
To the best of our knowledge, there are no studies describing
the effect of GOS/FOS mixtures on epithelial cell responses.
However, since both GOS and FOS do have direct effects on
epithelial cells (Akbari et al. 2015, 2017), we also expect mix-
tures of GOS and FOS to exert beneﬁcial effect on epithelial
barrier integrity.
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3.3.4. Effects of GOS/FOS mixtures on prevention of
infection and support of immunity
The immune system can be modulated by GOS/FOS mixtures,
but the majority of these effects are likely to be the result of the
effect of NCDs on microbiota. Establishing a balanced micro-
biome is important to establish normal immune responses as
imbalances, or dysbiosis, can cause disease (Kau et a. 2011). It
has been shown that infant formula substituted with a mixture
of scGOS/lcFOS (9:1) reduced the incidence of atopic dermati-
tis during the ﬁrst six months of life (Moro et al. 2006). A mix-
ture of oligosaccharides also had beneﬁcial effects on mucosal
immunity in low-atopy-risk infants (Gruber et al. 2010) and
even after ﬁve years a protective effect on the incidence of cer-
tain allergic manifestations was observed (Arslanoglu et al.
2012). Scholtens et al. (2008) performed an in vivo study to
investigate the effect of GOS/FOS supplementation on the
development of the fecal secretory IgA (sIgA) response. Supple-
mentation of infant formula with 6g/L scGOS/lcFOS (ratio 9:1)
resulted in higher concentrations of fecal sIgA after 26 weeks in
infants exclusively fed with formula, suggesting a positive effect
on mucosal immunity (Scholtens et al. 2008).
3.4. Pectin oligomers
Pectins are polysaccharides rich in galacturonic acid molecules.
These galacturonic acid molecules form the backbone of the
molecule (Brejnholt 2009). The backbone structure can have
side chains of neutral sugars e.g., arabinose, rhamnose, and
galactose (Brejnholt 2009). Some carboxylgroups on the galac-
turonic acid backbone can be esteriﬁed by methyl groups
(Brejnholt 2009). The percentage of methyl-esteriﬁed galactur-
onic acid units in the pectin chain is known as the degree of
methylation (DM) and is used to classify the pectins into differ-
ent categories (Brejnholt 2009) with different physicochemical
properties. These different pectins have different in health pro-
moting effects (Vogt et al. 2016).
3.4.1. Effects of POS on microbiota composition
Although there are no commercially available pectin-supple-
mented infant formulas yet, pectin and/or modiﬁed pectins have
been shown to have several beneﬁcial effects in experimental
studies related to infant formula (Jeurink et al. 2013). This may
make these NDCs suitable for the supplementation in infant
formula in the near future. Recently Di et al. (Di et al. 2017)
studied the potential prebiotic effects of 5 different pectin oligo-
saccharides (POS) structures, which can be obtained from pectin
by enzymatic treatment and acid hydrolysis (Di et al. 2017). It
was found that POS exhibited prebiotic activity in in vitro batch
fermentation studies and enhancing effects on numbers of
Biﬁdobacteria over time. However, the biﬁdogenic effect was not
the same for all POSs tested and seems to be dependent on
structure. Especially the arabinose-rich rhamnogalacturonic acids
were responsible for the prebiotic effects (Di et al. 2017).
3.4.2. POS and prevention of pathogen adhesion
POS can serve as decoy receptors to neutralize toxins produced
by pathogens. Olano-Martin and coworkers (Olano-Martin
et al. 2003) evaluated pectins and POS fractions and their abil-
ity to interfere with the toxicity of Shiga-like toxins from
Escherichia coli O157:H7 in an in vitro experiment using the
HT29 cell line. Medium supplemented with different concen-
trations of pectins or POS fractions was preincubated with
Shiga-like toxins and subsequently added to the cell culture.
After 48 hours, cytotoxicity was measured and compared with
cells incubated with only Shiga-like toxins. Addition of POS
fractions could protect cells from damage induced by Shiga-like
toxins. Pectin polymers protected cells in a lower extend com-
pared to POS fractions (Olano-Martin et al. 2003). There are
no speciﬁc studies investigating the direct pathogen-binding
abilities of POS.
3.4.3. Effects of POS on epithelial cell responses
Pectin molecules have the ability to directly inﬂuence epithelial
cell responses. In a study by Vogt et al. (2016), lemon pectins
originated were found to stimulate barrier function in an in
vitro experiment with a T84 epithelial cells. Incubation with
lemon pectins had a protective effect on barrier function mea-
sured by transepithelial electrical resistance (Vogt et al. 2016).
3.4.4. Effects of POS on prevention of infection and support
of immunity
There are also many studies demonstrating immune modula-
tory effects of POS and of oligosaccharide mixtures containing
POS (Stam et al. 2011; Vos et al. 2010). In the study of Vos
et al. (Vos et al. 2010) the kinetic effects of immune modulation
by a mixture of oligosaccharides and the correlation between
microbiological and immunological parameters were studied in
a murine vaccination model. In this study C57BL/6 mice were
supplemented with scGOS and lcFOS (ratio 9:1) in combina-
tion with pectin derived acidic oligosaccharides (pAOS). It was
found that the early phase of the vaccine-speciﬁc immune
response could be inﬂuenced by this supplementation i.e. it
could increase the delayed-type hypersensitivity (DTH)
responses. Analysis of the microbiological parameters showed
there was a correlation between the increased percentage of
cecal lactobacilli and the increased DTH responses, suggesting
that microbiota might play a role in this time-speciﬁc immune
modulating effect. Stam et al. (Stam et al. 2011) also used a mix-
ture of oligosaccharides (scGOS/lcFOS ratio 9:1 and pAOS) to
study speciﬁc immunoglobulin responses to Haemophilus
inﬂuenza type b (Hib) and tetanus immunization in healthy
non-atopic infants during the ﬁrst year of life. Although there
are many studies reporting modulating effects of prebiotics on
the immune responses in infants at risk of allergy, in this study
with healthy infants no effects of supplementation of food for-
mulas with the oligosaccharide mixture were found on anti-
body speciﬁc levels when compared with children on control
diets. Therefore, the authors hypothesized that the oligosaccha-
ride mixture might promote T-helper 1 (Th1) and T-regulatory
(Treg) immune responses and downregulate of IgE-mediated
allergic responses, but it does not affect the normal vaccine-spe-
ciﬁc serum antibody response (Stam et al. 2011).
4. In vitro systems to test NDC effects?
Several studies have shown that other, more effective NDCs
might become available if we had faster and more predictive
means to unravel the structure/function relationships of HMOs
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and NDCs and their effects on health parameters described
above (Bermudez-Brito et al. 2015a; Bermudez-Brito et al.
2015b). Processes that directly after birth should be enforced are
not only the prevention of pathogen adhesion, but for example
also the transition from a Th2 environment in utero towards a
more Th1 environment to allow the baby to respond to patho-
gens (Nussbaum and Sperandio 2011). How and which HMOs
have such an effect is unknown but it is an important phenome-
non in immune maturation (Nussbaum and Sperandio 2011).
Also, it is predictable that infant formulas should be different for
healthy and disease-prone infants. For example, prematures are
born with a rather proinﬂammatory, Th1 like phenotype and
should be fed with NDC supplements preventing overt immune
responses to avoid necrotizing enterocolitis (Martin and Walker
2006). Also, allergic prone infants with the risk to develop a too
strong Th2 response might beneﬁt from speciﬁc infant formulas
to manage the allergy and priming with potential allergens
(Moro et al. 2006; Stam et al. 2011). Invasive experiments in
infants obviously have great restrains and as a consequence, the
number of in vivo studies is limited and such studies can only
be done when safety is guaranteed. The ﬁeld would greatly bene-
ﬁt from a physiological relevant in vitro model of the infant
intestine for testing efﬁcacy of NDCs. Such an in vitro model of
in infant intestine should meet a number of prerequisites. It
should contain a polarized epithelium cell layer, microbiota and
presence of (immature) immune cells. In this way utilization of
NDCs and effects on immunity and microbiota communities as
well as its cross-talk with the immature immune cells can be
studied ex vivo and serve at least as selection tool for infant for-
mula applicable NDCs.
4.1. Challenges for developing a new in vitro model
A major challenge for creating a physiological relevant in vitro
model is the creation of a microenvironment in which both aer-
obic epithelial cells and aerobic as well as anaerobic microbiota
species can survive and exchange information (Ulluwishewa
et al. 2015). About 90% of the commensal microbiota are obli-
gate anaerobes and therefore should be cultured in an anaero-
bic environment. For example, certain Biﬁdobacteria species
show different growth patterns when they come in contact with
oxygen (Ruiz et al. 2011). To overcome this problem, many
studies use ultraviolet (UV)-killed bacteria or bacterial compo-
nents. This, however, might not reﬂect the physiological situa-
tion as there are studies reporting that live bacteria exert
greater beneﬁcial effects than non-viable bacteria (Ulluwishewa
et al. 2015). Furthermore, the absence of living bacteria in an in
vitro system leads to the absence of components secreted by
bacteria.
For co-culturing human eukaryotic cells and living bacteria,
an anaerobic compartment should be created in an in vitro sys-
tem mimicking the infant gut intestine. Currently there are two
models published in which cell-cultures are combined with
anaerobic bacteria-cultures. Sadabad et al. (Sadabad et al. 2015)
developed a coculture system called the “Human oxygen-Bacteria
anaerobic (HoxBan) coculture system’ in which coverslip
attached Caco-2 cells in 10 mL DMEM medium were placed on
top of F. Prausnitzii bacteria grown in YCFAG-agar in 50mL
culture tubes. This was done in order to study interactions
between F. Prausnitzii and epithelial cells. In another study, Ullu-
wishewa et al. (Ulluwishewa et al. 2015) used a unique apical
anaerobic model of the intestinal epithelial barrier, which enabled
co-culturing of living obligate anaerobes with Caco-2 cells. In
this model a trans well insert with a human intestinal epithelial
Caco-2 cell monolayer was ﬁtted on a chamber lid. This sealed of
a chamber ﬁlled with aerobic cell culture medium from the
anaerobic environment. The insert was ﬁlled with anaerobic cell
culture medium (Ulluwishewa et al. 2015). In this way, the Caco-
2 cells were exposed to an aerobic environment on the basal side,
while the apical side was exposed to an anaerobic environment,
making it able to co-culture human intestinal epithelial Caco-2
cells with anaerobic bacteria in the apical compartment
(Ulluwishewa et al. 2015).
Although both research systems were successful in combin-
ing cell-cultures with anaerobic bacteria-cultures, a more spe-
ciﬁc model is needed to test NDC effects, since the model of
Sadabad et al. (Sadabad et al. 2015) applied agar for growing
bacteria. Although this is a simple and logical way to create an
anaerobic compartment, it will not be possible to study NDC
fermentation, since agar will be fermented as well and interfere
with studies on fermentation and utilization of the NDCs. The
model of Ulluwishewa et al. (Ulluwishewa et al. 2015) only
used a single bacteria strain in the anaerobic compartment. To
test NDC effects, whole microbiota samples should be applied.
5. Concluding remarks
In the past decades, more knowledge has become available
about the functions HMOs serve. Unique features of HMOs
include the possibility to modulate and manage microbiota
composition in a beneﬁcial way by stimulating growth of Biﬁ-
dobacteria, modulate immune reactions, defend against infec-
tions and change gut epithelial cell responses (Bode 2006). By
doing so HMOs are very important for guiding immune barrier
development and maintenance of health in infants. As HMOs
are unique for HM, these beneﬁcial effects are lost in neonates
fed with cow’s-milk derived infant formula. Substitution of
infant formula with adequate NDCs to substitute HMO func-
tions is therefore very important and effects might not only
inﬂuence health in early but also in later life. For example, an
adequate colonization of microbiota in early-life helps to main-
tain health by reducing the incidence of inﬂammatory, autoim-
mune and atopic diseases (Martin et al. 2010).
Although currently the substitution of infant formula with
NDCs is mainly focused on the prebiotic effects, more attention
should be given to the direct beneﬁcial immune effects which
are independent of microbiota. There are many immune mod-
ulating effects of NDCs (Bermudez-Brito et al. 2015a; Bermu-
dez-Brito et al. 2015b; Vogt et al. 2016). An important function
of the NDCs in infant formula is to guide the transition from a
Th2 environment in utero towards a more Th1 environment to
allow the baby to respond to pathogens. Disturbance of this
transition, as seen in prematures, could cause the immune sys-
tem to react with proinﬂammatory cytokine production and
secretion of antibacterial peptides, increasing the risk of devel-
opment of (allergic) disease in later life. Recent work of Bermu-
dez-Brito et al. (Bermudez-Brito et al. 2015b) showed that not
all NDCs currently described for infant formula do support the
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induction of Th1 responses. Depending on its composition the
NDCs either promote Th1, Th2 or Treg responses. For this rea-
son, more research is needed to understand the speciﬁc effects
of NDCs. When speciﬁc NDCs can be linked to beneﬁcial
health effects this information can be used to better mimic the
functional activities of HM components and more speciﬁc of
HMOs. Furthermore, it might be possible to design NDC mix-
tures that support the development of healthy immune
responses in a controlled and intelligent way, as this composi-
tion is probably different for healthy and disease-prone infants.
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